Publications by authors named "Tatsuru Hiraga"
Article Synopsis
- Cabozantinib is effective for advanced renal cell carcinoma (RCC), but 60% of patients experience severe side effects requiring dose reductions; this study examines its impact in Japanese patients.
- Researchers measured cabozantinib trough concentrations in 10 Japanese RCC patients, finding higher concentrations correlated with better cancer control and increased adverse events.
- Results suggest monitoring cabozantinib levels could enhance treatment effectiveness and reduce serious side effects in Japanese patients with RCC.
Cabozantinib is an oral small-molecule tyrosine kinase inhibitor that has become a standard of care for advanced renal cell carcinoma (RCC). However, cabozantinib is associated with a high rate of adverse events. Therefore, individualised cabozantinib administration and monitoring could help maximise its therapeutic efficacy and avoid serious adverse events.
View Article and Find Full Text PDF